µÏÍþ¹ú¼Ê

µÏÍþÖƵÏÍþ¹ú¼Ê µÏÍþÖƵÏÍþ¹ú¼Ê

¼ò ¤™
  • ¼ò
  • ·±
  • EN
¤œ
Ïà¹ØÁ´½Ó
  • ½­ËÕºÀÉ­µÏÍþ¹ú¼ÊÒµ¼¯ÍÅÓÐÏÞ¹«Ë¾¥Y
ÐÂÎÅ·¢²¼
Press Release
Ê×Ò³  >  ÐÂÎÅÖÐÐÄ  >  ÐÂÎÅ·¢²¼
GLP-1RAÕæʵÊÀ½çÑо¿³É¹ûÔÚ¹ú¼ÊÆÚ¿¯·¢±í£¬µÏÍþÖƵÏÍþ¹ú¼ÊæÚÀ´ÃÀ?ΪDKD»¼Õß´øÀ´¸üÓÅÑ¡Ôñ
·¢²¼ÈÕÆÚ£º2024/08/08
×ÖºÅ

½üÈÕ£¬Ò»Ïî¹ØÓÚGLP-1ÊÜÌ弤¶¯¼Á£¨GLP-1RA£©ÖÎÁÆÌÇÄò²¡Éö²¡£¨DKD£©»¼ÕßµÄÕæʵÊÀ½çÑо¿³É¹ûÔÚ¹ú¼ÊÆÚ¿¯Diabetes, Metabolic Syndrome and Obesity£¨¡¶ÌÇÄò²¡£¬´úл×ÛºÏÖ¢ºÍ·ÊÅÖ¡·£©·¢±í¡£


ÕâÏîµ¥±Û¡¢»Ø¹ËÐÔ¡¢ÕæʵÊÀ½çÑо¿¹²ÄÉÈëÁË364Àý½ÓÊÜGLP-1RAÖÎÁÆÖÁÉÙ6¸öÔµÄÇáÖжÈDKD»¼Õߣ¬ÆäÖаüÀ¨¾ÛÒÒ¶þ´¼ÂåÈûÄÇëÄ£¨ÉÌÆ·Ãû£ºæÚÀ´ÃÀ?£©159Àý¡¢¶ÈÀ­ÌÇëÄ104Àý¡¢Ë¾ÃÀ¸ñ³ëÄ52Àý¡¢ÀûÀ­Â³ëÄ49Àý¡£Ö÷ÒªÖÕµãÊÇÖÎÁÆ6¸öÔÂʱµÄÌÇ»¯Ñªºìµ°°×£¨HbA1c£©Ë®Æ½[1]¡£

Ñо¿½á¹ûÏÔʾ£¬GLP-1RAÀàµÏÍþ¹ú¼ÊÎïÖÎÁÆ6¸öÔºó£¬Æ½¾ùHbA1cˮƽÏÔÖøϽµ1.77%£¬Äò°×µ°°×Ó뼡ôû±ÈÖµ£¨UACR£©Ï½µÁË40.3%£¬24СʱÄòµ°°×ºÍ¹ÀËãÉöСÇòÂ˹ýÂÊ£¨eGFR£©Ò²ÏÔÖø¸ÄÉÆ£¨¾ùp<0.001£©¡£´ËÍ⣬Óë»ùÏßÏà±È£¬»¼ÕߵĿո¹ÑªÌÇ¡¢ÌåÖØ¡¢ÑªÑ¹ºÍѪ֬Ïà¹ØÖ¸±ê¾ùÓÐÏÔÖø¸ÄÉÆ£¨¾ùp<0.001£©¡£

ÖµµÃ×¢ÒâµÄÊÇ£¬¾¡¹ÜʹÓþÛÒÒ¶þ´¼ÂåÈûÄÇëÄÖÎÁƵĻ¼ÕßÊýÁ¿×î¶à£¬µ«Æä賦µÀ·´Ó¦µÄ×Ü·¢ÉúÂÊ£¨17.6%vs30.6%~51%£©ºÍµÍѪÌÇ·¢ÉúÂÊ£¨3.1%vs8.2%~11.5%£©¾ùµÍÓÚÆäËüGLP-1RA¡£

Ñо¿»¹·¢ÏÖ£¬ÎÞÂÛÊÇ·ñʹÓÃѪ¹Ü½ôÕÅËØת»»Ã¸ÒÖÖƼÁ/Ѫ¹Ü½ôÕÅËØ¢òÊÜÌå×èÖͼÁ£¨ACEi/ARB£©ÀàÉö±£»¤µÏÍþ¹ú¼Ê£¬GLP-1RA¾ùÄܽµµÍµ°°×Äò£¬ÇÒÔ½ÔçʹÓÃGLP-1RAµÄ»¼Õ߸ÄÉÆÔ½Ã÷ÏÔ[1]¡£

DKDÊÇÊÇÌÇÄò²¡µÄÖ÷Òª²¢·¢Ö¢Ö®Ò»[2]¡£Ô¼ÓÐ30%¨C40%µÄÌÇÄò²¡»¼Õß°éÓÐDKD[3]£¬Êǵ¼ÖÂÖÕÄ©ÆÚÉö²¡(ESRD)µÄÖ÷ÒªÔ­Òò[4]¡£

¼ÈÍùÔøÓÐËæ»ú¶ÔÕÕÑо¿Ö¤ÊµÁ˾ÛÒÒ¶þ´¼ÂåÈûÄÇëĶÔÇáÖжÈDKD»¼ÕßµÄÁÆЧÓëÒ»ÏßµÄSGLT2ÒÖÖƼÁ´ï¸ñÁо»Ï൱£¬ÇÒ¾ßÓиÄÉÆÖ¬ÖÊˮƽµÄ¶îÍâ»ñÒæ[5]¡£ÕâÏîÕæʵÊÀ½çÑо¿ÔòÔÙ´Î֤ʵÁ˾ÛÒÒ¶þ´¼ÂåÈûÄÇëÄÄܹ»ÎªÇáÖжÈDKD»¼Õß´øÀ´½µÌÇ¡¢½µÑ¹¡¢¼õÖØ¡¢¸ÄÉÆѪ֬ºÍÑÓ»ºÉöÔà½øÕ¹µÈ¶àÖØ»ñÒ棬ÇÒÔÚ°²È«ÐÔÉÏÏà±ÈÆäËüGLP-1RA¸ü¾ßÓÅÊÆ£¬Õ⽫ÓÐÖú¸ÄÉÆ»¼ÕßµÄÉú»îÖÊÁ¿²¢Ìá¸ßÒÀ´ÓÐÔ¡£¾ÛÒÒ¶þ´¼ÂåÈûÄÇëĵĶàÖØ»ñÒæºÍ°²È«ÐÔÓÅÊƽ«ÎªDKD»¼Õß´øÀ´¸üÓŵÄÖÎÁÆÑ¡Ôñ¡£

Ñо¿³É¹û





GLP-1ÊÜÌ弤¶¯¼ÁÖÎÁÆ2ÐÍÌÇÄò²¡»¼ÕßÇáÖжÈÌÇÄò²¡Éö²¡µÄÕæʵÊÀ½çÑо¿£ºÒ»´Î»Ø¹ËÐÔµ¥±ÛÁÙ´²ÊÔÑé



Ñо¿±³¾°£º
ÐÄѪ¹Ü½á¾ÖÊÔÑé±íÃ÷ÒȸßѪÌÇËØÑùëÄ-1ÊÜÌ弤¶¯¼Á (GLP-1RA) ¶ÔÉöÔàÓÐÒ棻Ȼ¶ø£¬ÕæʵÊÀ½çÖйØÓÚÌÇÄò²¡Éö²¡£¨DKD£©µÄÁÆЧºÍ°²È«ÐÔÑо¿ÉÐÉÙ¡£
Ñо¿·½·¨£º
ÕâÏî»Ø¹ËÐÔ¡¢µ¥±ÛÕæʵÊÀ½çÑо¿Éæ¼°½ÓÊÜGLP-1RAÖÎÁÆÖÁÉÙ6¸öÔ嵀 DKD³ÉÈË¡£Ö÷ÒªÖÕµãÊÇ6¸öÔºóÌÇ»¯Ñªºìµ°°× (HbA1c) ˮƽ¡£
Ñо¿½á¹û£º
±¾Ñо¿¹²ÄÉÈë364ÀýDKD»¼Õߣ¬ÆäÖÐ153Àý£¨42.0%£©ÎªÅ®ÐÔ¡£ÖÐλ²¡³ÌΪ8.0Ä꣬ÄêÁä¡¢HbA1cˮƽ¡¢ÌåÖØÖ¸ÊýºÍÄò°×µ°°×¼¡ôû±ÈÖµ (UACR) µÄƽ¾ùÖµ·Ö±ðΪ52.1Äê¡¢8.6%¡¢27.8kg/m2ºÍ88.0mg/g¡£´ËÍ⣬73.6%ºÍ 26.4% µÄ»¼Õß·Ö±ð»¼ÓÐÇá¶ÈºÍÖжÈDKD¡£GLP-1RAÖÎÁÆ6¸öÔºó£¬Æ½¾ùHbA1cˮƽºÍUACR·Ö±ðϽµ1.77%ºÍ40.3%£¨¾ùp<0.001£©¡£Óë»ùÏßÆÚÏà±È£¬»¼ÕßµÄ 24 СʱÄòµ°°×¡¢¹À¼ÆÉöСÇòÂ˹ýÂÊ£¨eGFR£©¡¢¿Õ¸¹ÑªÌÇ¡¢ÌåÖØ¡¢ÊÕËõѹ£¨SBP£©¡¢ÊæÕÅѹ£¨DBP£©¡¢×ܵ¨¹Ì´¼¡¢¸ÊÓÍÈýõ¥¡¢¸ßÃܶÈÖ¬µ°°×µ¨¹Ì´¼ºÍµÍÃܶÈÖ¬µ°°×µ¨¹Ì´¼¾ùÏÔןÄÉÆ£¨¾ùp<0.001£©¡£²¡³Ì<10 ÄêµÄ»¼Õ߱Ȳ¡³Ì¡Ý10 ÄêµÄ»¼ÕßÔÚ HbA1c ˮƽ¡¢UACR ºÍ eGFR ·½ÃæÓиüÏÔ×ŵı仯£¨ËùÓÐ p<0.001£©¡£Í¬Ê±·þÓÃѪ¹Ü½ôÕÅËØת»»Ã¸ÒÖÖƼÁ/Ѫ¹Ü½ôÕÅËØIIÊÜÌå×èÖͼÁ (ACEis/ARB) µÄ»¼ÕßµÄSBPºÍDBP±ä»¯±Èδ·þÓÃACEis/ARBµÄ»¼Õ߸üÏÔÖø£¬¶øUACRºÍeGFRµÄ±ä»¯Ã»ÓÐÏÔ×ŲîÒì¡£

Ñо¿½áÂÛ£º

6¸öÔµÄGLP-1ÊÜÌ弤¶¯¼Á£¨GLP-1RA£©ÖÎÁÆ¿ÉÒÔ¸ÄÉÆÇá¶ÈÖÁÖÐ¶È DKD »¼ÕßµÄѪÌÇ¡¢ÑªÑ¹¡¢ÑªÖ¬ºÍÌåÖØ£¬Í¬Ê±¼õ»ºÉöÔ༲²¡µÄ·¢Õ¹¡£Ëü¶ÀÁ¢ÓÚѪ¹Ü½ôÕÅËØת»»Ã¸ÒÖÖƼÁ£¨ACEi£©/Ѫ¹Ü½ôÕÅËØÊÜÌåÞ׿¹¼Á£¨ARB£©µÄÓ°Ïì¶ø½µµÍµ°°×Äò£¬²¢ÇÒÔçÆÚʹÓÿÉÒÔ¸ü¿ì²úÉúЧ¹û£¬ÕâÖ§³ÖÁË»ùÓÚÖ¤¾ÝµÄÁÙ´²Êµ¼ù¡£


²Î¿¼ÎÄÏ×£º

[1] Ying Liu et al. Real-world clinical effectiveness of glucagon-like peptide-1 receptor agonist on mild-to-moderate diabetic kidney disease in patients with type 2 diabetes: a retrospective, single-arm clinical trial.Diabetes, Metabolic Syndrome and Obesity 2024:17 2913¨C2921. 

[2] Mohandes S, Doke T, Hu H, et al. Molecular pathways that drive diabetic kidney disease. J Clin Invest. 2023;15;133:e165654. 

[3] Bonner R, Albajrami O, Hudspeth J, et al. Diabetic kidney disease. Prim Care. 2020;47:645-659.

[4] Mima A, Nomura A, Fujii T. Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: a narrative review. Biomed Pharmacother. 2023;165:115032.

[5] Cao Y, Cao S, Zhao J, Zhao J, Zhao Y and Liu Y (2024) Efficacy and safety of polyethylene glycol loxenatide in treating mild-to-moderate diabetic kidney disease in type 2 diabetes patients: a randomized, open-label, clinical trial.Front. Endocrinol. 15:1387993.


¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê

µÏÍþÖƵÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖƵÏÍþ¹ú¼ÊÆóÒµ£¬ÏÂÊôºÀÉ­µÏÍþ¹ú¼ÊÒµ¡¢³£Öݺã°îµÏÍþ¹ú¼ÊÒµ¡¢µÏÍþÉúÎïÒ½µÏÍþ¹ú¼ÊµÈ×Ó¹«Ë¾£¬Öصã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾­ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò£¬ÖÂÁ¦ÓÚͨ¹ý³ÖÐø´´ÐÂÌá¸ßÈËÀàÉúÃüÖÊÁ¿¡£½ØÖÁÄ¿Ç°£¬¹«Ë¾ÒÑÉÏÊÐ7¿î´´ÐµÏÍþ¹ú¼Ê£¬´´Ð²úÆ·ÓªÊÕÕ¼±È´ï67.9%¡£¹«Ë¾Á¬Ðø¶àÄêλ¾ÓÈ«ÇòÖƵÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖصã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£¹«Ë¾ÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£¸ü¶àÐÅÏ¢Çë·ÃÎÊ£º/¡£


Ç°Õ°ÐÔ˵Ã÷


±¾ÎÄÖ¼ÔÚÌṩÓйء°µÏÍþÖƵÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¡±»òÆä×Ó¹«Ë¾µÈ¹ØÁª·½£¨Í³³Æ¡°¹«Ë¾¡±£©µÄÏà¹ØÐÅÏ¢£¬²»¹¹³É¹«Ë¾ÐÅÏ¢Åû¶»òͶ×ÊÍƼö¡£

±¾ÎÄËù·¢²¼µÄÐÅÏ¢ÖпÉÄÜ»á°üº¬Ä³Ð©Ç°Õ°ÐÔ±íÊö£¬ÀýÈçÉæ¼°ÒµÎñºÍ²úÆ·Ç°¾°£¬»ò¹«Ë¾¼Æ»®¡¢ÈÏÖª¡¢Ô¤ÆÚ¼°²ßÂÔ¡£ÕâЩ±íÊöÊǽ¨Á¢ÔÚÍƲâÐÔ¼ÙÉèµÄÊý¾Ý»ù´¡ÉϵÄÔ¤²â£¬²¢·ÇÊǶÔδÀ´·¢Õ¹µÄ±£Ö¤£¬ÒòÆäÐÔÖÊʹȻ¾ùÊÜÏà¹Ø·çÏպͲ»È·¶¨ÒòËØÓ°Ï죬ÆäÖв¿·Ö»¹²»Êܹ«Ë¾¿ØÖÆÇÒÄÑÒÔÔ¤ÁÏ£¬Í¶×ÊÕß½øÐÐͶ×ʾö²ßʱӦ½÷É÷ʹÓá£ÔÚʹÓá°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°ÆÚÍû¡±¼°ÆäËûÀàËÆ´ÊÓï½øÐбíÊöʱ£¬·²Ó빫˾ÓйصÄÐÅÏ¢±íÊö£¬¾ùÊôÓÚÇ°Õ°ÐÔ±íÊö¡£¹«Ë¾²¢ÎÞÒåÎñ¸üлòÐÞ¸ÄÕâЩǰհÐÔ±íÊö£¬¹«Ë¾¡¢¹«Ë¾¶­Ê¡¢¹ÍÔ±¡¢´úÀí¸Å²»³Ðµ£ÒòÈκÎÇ°Õ°ÐÔ±íÊö²»ÄÜʵÏÖ»ò±ä³É²»ÕýÈ·¶øÒýÖµÄÈκÎÔðÈΡ£

±¾ÐÂΟåÖеÄËùÓÐÐÅÏ¢½ö¼°ÓÚÐÂΟ巢²¼Ö®ÈÕ£¬ÎÞÂÛÊÇ·ñ³öÏÖÐÂ×ÊÁÏ¡¢Î´À´Ê¼þ»òÆäËûÇé¿ö£¬³ý·Ç·¨ÂÉÒªÇ󣬹«Ë¾²¢ÎÞÔðÈλòÒåÎñ¸üлòÐ޸ĸõÈÐÅÏ¢¡£Í¶×ÊÕßÒ˲ÎÕÕµÏÍþÖƵÏÍþ¹ú¼Ê£¨03692.HK£©¹«¸æ¼°²Æ±¨£¬ÒÔ»ñÈ¡½öÓëÉÏÊй«Ë¾ÓйصÄÐÅÏ¢¡£


¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿